Source: European Medicines Agency (EU) Revision Year: 2020 Publisher: Basilea Pharmaceutica Deutschland GmbH, Marie-Curie-Strasse 8, 79539, Lรถrrach, Germany
CRESEMBA 100 mg hard capsules.
Pharmaceutical Form |
---|
Hard capsule. Swedish Orange (reddish-brown) capsule body marked with “100” in black ink and a white cap marked with “C” in black ink. Capsules length: 24.2 mm. |
For the full list of excipients, see section 6.1.
Each capsule contains 100 mg isavuconazole (as 186.3 mg isavuconazonium sulfate).
Active Ingredient | Description | |
---|---|---|
Isavuconazole |
Isavuconazole is an active form of isavuconazonium. Isavuconazole inhibits lanosterol 14-alpha demethylase (or CYP51A1) and leads to the accumulation of ergosterol toxic precursors in the fungal cytoplasm. Isavuconazole is indicated for the treatment of invasive aspergillosis and invasive mucormycosis. |
List of Excipients |
---|
Capsule contents: Magnesium citrate (anhydrous) Capsule shell: Hypromellose Printing ink: Shellac |
14 hard capsules (in two aluminum blisters), with each capsule pocket connected to a pocket with desiccant.
Basilea Pharmaceutica Deutschland GmbH, Marie-Curie-Strasse 8, 79539, Lรถrrach, Germany
EU/1/15/1036/002
Date of first authorisation: 15 October 2015
Drug | Countries | |
---|---|---|
CRESEMBA | Austria, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, United Kingdom, United States |
ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.